Vanguard Group Inc. Has $24.83 Million Holdings in REGENXBIO Inc. $RGNX

Key Points

• Vanguard Group Inc. increased its stake in REGENXBIO Inc. by 16.3%, holding approximately 3.47 million shares worth about $24.83 million after purchasing additional shares in the first quarter.
• REGENXBIO's recent earnings report showed a loss per share of ($1.38), missing analysts' estimates, with revenue of $21.36 million compared to expectations of $40.87 million.
• Equity analysts have mixed views on REGENXBIO, with price targets ranging from $17.00 to $52.00, resulting in an average rating of "Moderate Buy" with a target price of $28.38.

Vanguard Group Inc. increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 16.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,472,988 shares of the biotechnology company's stock after acquiring an additional 487,036 shares during the quarter. Vanguard Group Inc. owned 6.93% of REGENXBIO worth $24,832,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. FNY Investment Advisers LLC acquired a new stake in shares of REGENXBIO during the first quarter valued at approximately $35,000. Laurion Capital Management LP acquired a new stake in shares of REGENXBIO during the fourth quarter valued at approximately $79,000. Pallas Capital Advisors LLC acquired a new stake in shares of REGENXBIO during the first quarter valued at approximately $74,000. Tower Research Capital LLC TRC raised its holdings in shares of REGENXBIO by 442.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 10,714 shares during the period. Finally, Corton Capital Inc. acquired a new stake in shares of REGENXBIO during the fourth quarter valued at approximately $103,000. Institutional investors and hedge funds own 88.08% of the company's stock.

REGENXBIO Stock Down 0.9%

RGNX stock traded down $0.08 during trading hours on Monday, hitting $8.93. The company's stock had a trading volume of 467,067 shares, compared to its average volume of 690,520. The company has a market capitalization of $451.05 million, a PE ratio of -2.60 and a beta of 1.17. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $13.48. The stock has a 50 day moving average price of $8.55 and a two-hundred day moving average price of $8.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The business had revenue of $21.36 million during the quarter, compared to the consensus estimate of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. Sell-side analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a report on Saturday, August 9th. HC Wainwright reaffirmed a "buy" rating and set a $34.00 price objective on shares of REGENXBIO in a research report on Tuesday, August 19th. Royal Bank Of Canada lowered their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Barclays lowered their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, REGENXBIO has an average rating of "Moderate Buy" and a consensus price target of $28.38.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.